Colchicine in acute coronary syndromes: the present and the possible future

IF 41.7 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Nature Reviews Cardiology Pub Date : 2025-01-28 DOI:10.1038/s41569-025-01124-3

Massimo Imazio, Federico Ballacci, Federica Giordano

引用次数: 0

Abstract

Inflammation is a new therapeutic target for the prevention of cardiovascular disease. Colchicine is a potential cheap option to target inflammation and prevent atherosclerotic plaque destabilization. We discuss major clinical trials and guidelines on the use of colchicine in patients with coronary syndromes, especially acute coronary syndromes, in whom results have been conflicting.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Cardiology 医学-心血管系统

CiteScore

53.10

自引率

0.60%

发文量

143

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cardiology aims to be the go-to source for reviews and commentaries in the scientific and clinical communities it serves. Focused on providing authoritative and accessible articles enriched with clear figures and tables, the journal strives to offer unparalleled service to authors, referees, and readers, maximizing the usefulness and impact of each publication. It covers a broad range of content types, including Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives, catering to practising cardiologists and cardiovascular research scientists. Authored by renowned clinicians, academics, and researchers, the content targets readers in the biological and medical sciences, ensuring accessibility across various disciplines. In-depth Reviews offer up-to-date information, while Consensus Statements provide evidence-based recommendations. Perspectives and News & Views present topical discussions and opinions, and the Research Highlights section filters primary research from cardiovascular and general medical journals. As part of the Nature Reviews portfolio, Nature Reviews Cardiology maintains high standards and a wide reach.